WVE-006 for Alpha-1 Antitrypsin Deficiency

WVE-006 for Alpha-1 Antitrypsin Deficiency
80%68%57%May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 20 • YES 60.4%May 21 • YES 65.6%May 22 • YES 66.0%May 24 • YES 76.1%
Wave Life Sciences Ltd. ($WVE)
No stock closeNo stock closeNo stock close$7.30$6.79$6.28May 8May 9May 10May 11May 12May 13May 14May 15May 16May 17May 18May 19May 20May 21May 22May 23May 24May 8 • WVE $7.18May 11 • WVE $7.07May 12 • WVE $6.79May 13 • WVE $6.99May 14 • WVE $6.90May 15 • WVE $6.77May 18 • WVE $6.40
ResolvedPositive
Oracle Evidence
ClinicalNewsTrialPositionsReasoningOracle

Matched news4 items

All news
WVE

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference

Data from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.

Presentation / AbstractMatched wve-006, alpha-1, antitrypsin, deficiency, editing
WVE

Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing

Data reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing On track for feedback from FDA on potential accelerated approval pathway mid-2026

Interim Data • Phase 1/2Interim data Mon, May 18, 2026Matched wve-006, alpha-1, antitrypsin, deficiency, editing
WVE

Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the trial remains on track to initiate in 2Q 2026 Combination and maintenance trials of WVE-007 on track

Results Call • Phase 1/2Matched wve-006, alpha-1, antitrypsin, deficiency, editing
WVE

Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle mass Planning underway to initiate Phase 2a multidose portion of WVE-007 INLIGHT

Interim Data • Phase 1Matched wve-006, alpha-1, antitrypsin, deficiency, editing